Member Info for Inkose

To understand the process see

https://www.phrma.org/advocacy/research-development/clinical-trials

Yes I have bought some more this morning via spreadbet....
===========================================
Using a spread is dangerous.
To all other readers don't do it unless you really understand that your losses could be huge.

I have BHP Bilton, S32, Shell and Chevron amongst my holdings.
As I wrote 25% of my portfolio in in Pharma and Biotech. Overall the portfolio is comfortably up but there are a few horrid red patches.
As I wrote I would continue to monitor before I jumped in. (down 1.5p at the close today I see.
One possible source for ideas is to have a look at what Neil Woodford has in his biotech folios. He obligingly puts them on the web. I'd also say do have a look at IBT.

As Always DYOR. and if it seems too good to be true then it probably isn't.

Be warned! This is high risk. IMHO it would be unwise to put more than 5% of your investable pot into this company prior to the human trials.
Trials are exactly that and in Pharma most fail, as Neil Woodford found with Prothenahttps://www.onenewspage.com/n/Business/1zj7iv9ru3/Woodford-backed-Prothena-collapses-as-it-scraps-development.htm
You have many posts credited to you name. Are you generally an experienced investor and just new to Biotech?
What I am saying will not be popular on this board. I have followed the company for many years but (thankfully) never invested. I will continue to monitor but I won't be investing any time soon.
Good luck and above all DYOR.

Oh if only I new that about any company.
I am not giving advice but I would/will wait to see if there are any concrete developments before I investing. If it's positive you may miss out on some profits but if it is going to be as big as others posting here are convinced it will be there will still be lots to be had.
Here is the summary of the last 5 years performance:

https://uk.advfn.com/stock-market/london/avacta-AVCT/share-price-history

It also depends on how much you have to risk.

About 25% of my portfolio is in Pharma and Biotech. Most of it directly into shares but some into International Biotechnology Trust - (IBT) and pays a 4% dividend.
My outlook is to get rich slowly but get rich

WO:
"Now faith is the assurance of things hoped for, the conviction of things not seen."
Hebrews 11 vs 1

AstraZeneca confirmed Monday it had agreed to sell the commercial rights in Europe for its hypertension and heart failure treatment to Cheplapharm for $200m. Under the terms of the agreement, AstraZeneca had received a payment of $200m from Cheplapharm for hypertension and heart failure treatment Atacand and Atacand Plus. A time-bound payment of $10m as well as sales-contingent milestones would also be payable, AstraZeneca said. AstraZeneca said it would continue to manufacture and supply Atacand and Atacand Plus under a supply agreement and continue to commercialise the medicines in all markets where it still held the rights. Story provided by StockMarketWire.com

The Tory party will largely take the political blame
(Unfairly as it was a cross party issue) if there is
an economic hit.
============================
No not unfairly. This is an unnecessary crisis created by the Conservative lunatic right.
They will pay the price in coming elections and be out of power for a generation just as they were over the repeal of the Corn Laws.

Glaxosmithkline said its ViiV Healthcare joint venture had submitted a marketing authorisation application to the European Medicines Agency for a single-tablet, two-drug regimen for the treatment of HIV. The submission was based on studies that included more than 1400 infected adults, the results of which were presented at the 2018 International AIDS Society meeting in July. A new drug application to the US FDA was planned for the single tablet regimen for October. Other global regulatory submissions of dolutegravir and lamivudine as a single-tablet, two-drug regimen were anticipated in the coming months. At 1:09pm: (LON:GSK) GlaxoSmithKline PLC share price was -9.7p at 1485.9p Story provided by StockMarketWire.com

Sep. 13, 2018 2:17 PM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
The FDA approves AstraZeneca's (AZN -1.1%) Lumoxiti (moxetumomab pasudotox-tdfk) injection for the treatment of adult patients with relapsed/refractory hairy cell leukemia (HCL) who have received at least two prior lines of systemic therapies, including a purine nucleoside analog.

Orphan Drug-tagged Lumoxiti is an anti-CD22 recombinant immunotoxin. It consists of an antibody that binds to protein found on B-lymphocytes (CD22) that is fused to a toxin. Once the molecule is internalized by the cancer cell, the toxin leads to cell death by inhibiting protein translation. Specifically, the cell cannot read the information from messenger RNA so it cannot build proteins and dies.

Aug. 24, 2018 7:43 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor
The China National Drug Administration has approved AstraZeneca's (NYSE:AZN) LYNPARZA (olaparib) for the maintenance treatment of recurrent platinum-sensitive ovarian cancer, the first targeted therapy approved there for the indication.

The company is co-developing the PARP inhibitor with Merck (NYSE:MRK).

Just bought in as part of my inheritance tax portfolio

AstraZeneca said Wednesday results from a recent study showed its drug to improve lung function in patients with moderate to very severe chronic obstructive pulmonary disease was not more effective than alternative treatments. The 24-week AERISTO Phase IIIb trial was designed to assess the efficacy and safety of the company's disease treatment, Bevespi Aerosphere, compared with umeclidinium and vilanterol. 'The primary endpoints were peak change from baseline in FEV1 where non-inferiority and superiority were measured and change from baseline in trough FEV1 where non-inferiority was measured,' the company said. AstraZeneca said the results were 'inconsistent' with a previous trail that had demonstrated the efficacy and safety of the treatment to improve lung function. 'The efficacy and safety of Bevespi Aerosphere has been established by the Phase III PINNACLE trial programme involving more than 5,000 patients. The performance of Bevespi Aerosphere in AERISTO is inconsistent with previous data,' said Dr Colin Reisner, Head of Respiratory, Global Medicines Development. 'Bevespi Aerosphere is currently under review by the European Medicines Agency with a regulatory decision anticipated in the second half of 2018,' the company added. Story provided by StockMarketWire.com

You need a little more research, inkose.
===============================
Yes I do, as do we all.
I will let you know if I change my mind about Avacta.

when Affimers are proven to be totally safe in humans which should be sometime in 2019
=================================
That's not going to be achieved by 2019.
See https://en.wikipedia.org/wiki/Phases_of_clinical_research

The placing was to be able to fund a phase 1 trial. At the rate of current cash burn Avacta would run out of money before the trial was completed.
Trials are risky as share holders of Prothena found to their costs
Now read on:

“The entire process of developing a drug from preclinical research to marketing can take approximately 12 to 18 years and often costs well over $1 billion.” That is assuming that the trials are a “clinical success”.
It all seemed so promising for Prothema before the Phase III trial…

“We have just heard from Prothena that the Pronto trial, investigating NEOD001 in AL Amyloidosis, has not met its primary endpoint. This is an extremely disappointing outcome and one which has surprised the company, with a much bigger and more significant placebo effect being observed than anything seen in prior trials would have suggested. As a result, Prothena has announced that it will halt all spending on NEOD001 immediately, including the termination of the ongoing Vital study, which had been due to read-out next year.”

Well in May 2015 there was a placing at £1.25 (market price just a month or so previously was 63p) and the shares rapidly advanced to £1.48, but since then it has been a consistent erosion of the price. In analyst briefings they obviously tell a very good story.
What would worry me if I was holding these shares is the question of why, if the technology is so good and will return billions, they have not been bought by one of the big pharma groups.
I do have substantial holdings in AZN, GSK, MRK JNJ , ABBV, ABBT and others but as I said in my first post not in AVCT and have no plans to do so

I have been "monitoring" this share for at least 5 years. In those days the share price was the equivalent of about £3.00 (3p but there was a 100:1 share consolidation).
They have interesting technology BUT they are not unique.
I've rated it a "Strong Sell" but what I really mean is NEVER BUY.